GlassScriptPhysician profile
Rashmi Reddy
NPI 1376072603
$1,239.73
in general payments reported to CMS, 2019-2025
22 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $145 · 2024: $46.17 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.10 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $181.25 | 2025 | |
| Neurocrine Biosciences, INC. | $124.27 | 2022 | |
| Lilly USA, LLC | $121.84 | 2025 | Zepbound, Mounjaro |
| Xeris Pharmaceuticals, INC. | $105.81 | 2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $89.65 | 2025 | Tymlos |
| Novo Nordisk INC | $89.35 | 2025 | Ozempic, Wegovy |
| Mannkind Corporation | $79.16 | 2025 | |
| Medtronic, INC. | $74.61 | 2025 | Minimed 780g |
| Amgen INC. | $65.00 | 2025 | Evenity, Repatha |
| Tandem Diabetes Care, INC. | $46.17 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $37.10 | 2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $37.07 | 2025 | Yorvipath |
| Abbvie INC. | $30.21 | 2025 | |
| Soleno Therapeutics, INC. | $22.91 | 2025 | Vykat Xr |
| Astrazeneca Pharmaceuticals LP | $20.86 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.13 | 2025 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $18.42 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $17.70 | 2025 | |
| Invivyd INC | $15.71 | 2025 | Pemgarda |
| Sequel Med Tech, LLC | $14.91 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.50 | 2025 | Jardiance |
| Pfizer INC. | $14.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.